Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colistin + neomycin followed by fecal microbiota transplantation for intestinal ESBL-E/CRE decolonization
NL-OMON43965Phase 2Active, not recruiting
- Sponsor
- Prof. Stephan Harbarth; Hôpitaux Universitaires de Genève (HUG)
- Start
- Sep 2015
- Modality
- Peptides, Small Molecules, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of colistin, neomycin and allogeneic fecal microbiota in Intestinal colonization with extended-spectrum beta-lactamase-producing Enterobacteriaceae and gastrointestinal colonization with carbapenemase-producing Enterobacterales (2 arms), sponsored by Prof. Stephan Harbarth; Hôpitaux Universitaires de Genève (HUG). Primary endpoints: Restoration of the microbial ecology by a healthy intestinal bacterial flora and Eradication of intestinal carriage of ESBL-E or CPE. Started Sep 2015; status: active, not recruiting.
02
Drugs
colistinneomycinallogeneic fecal microbiota
03
Conditions
Intestinal colonization with extended-spectrum beta-lactamase-producing Enterobacteriaceaegastrointestinal colonization with carbapenemase-producing Enterobacterales
Beyond the preview
Go deeper on NL-OMON43965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43965.